Previous 10 | Next 10 |
home / stock / nvo / nvo articles
The skyrocketing demand for GLP-1 medications for weight loss is causing significant supply issues, often leaving type 2 diabetic patients without ...
On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight mana...
The famed Danish drug maker Novo Nordisk A/S (NYSE:NVO) expressed disappointment on Wednesday following a recommendation by the Dutch Health Care I...
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stock...
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 8.54% on an annualized basis producing an average annual return of 19...
Democratic U.S. Senate aides will meet with executives from Novo Nordisk A/S (NYSE:NVO) on Tuesday to discuss the ramifications of the company̵...
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial bu...
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of...
On Friday, the European Medicines Agency (EMA) warned patients using weight-loss drugs, such as Novo Nordisk A/S’s (NYSE:NVO) Wegovy, to info...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...